Chemoprevention Trial of Selenium and Prostate Cancer

摘要

The principal purpose of this trial is to assess the potential for the essential nutrient selenium (Se) to modulate biomarkers of prostate cancer between initial diagnostic biopsy and radical prostatectomy. The scope of work is to randomize at least 110 participants to either a placebo or Se dosages of 200 mug, or 400 mug/day. Recruitment is continuing as a result of a no-cost extension. A total of 79 subjects have been randomized. Of these, 72 have completed the study, 6 dropped before completing the study, and 1 is in the process of completing the study.